What are the differences in effects between tucatinib and 8201?

Tucatinib (Tucatinib, also known as tucatinib) and DS-8201 (Enhertu, generic name is trastuzumab-drustecan, Trastuzumab deruxtecan) are two targeted drugs for the treatment of HER2positive cancers. Although both can be applied to HER2positive breast cancer, their mechanisms, indications and therapeutic effects are significantly different. Understanding the characteristics of these two drugs can help doctors develop more appropriate treatment plans for patients.

From a mechanism of action perspective, tucatinib is a highly selective HER2 tyrosine kinase inhibitor that inhibits the growth of cancer cells by blocking the HER2 signaling pathway. Compared with other HER2 inhibitors, tucatinib has a smaller inhibitory effect on HER1 (EGFR), so the side effects are relatively mild. 8201 is an antibody drug conjugate (ADC) that combines anti-HER2 antibodies with cytotoxic drugs When connected, it can selectively kill HER2-expressing tumor cells and have stronger cytotoxicity to tumors. It is suitable for patient groups with high or even low HER2 expression.

In terms of therapeutic effect, the triple regimen of tucatinib combined with trastuzumab and capecitabine showed significant survival benefit in patients with brain metastases from HER2-positive breast cancer, especially in the control of central nervous system metastases. Multiple studies have shown that tucatinib has a significant effect in prolonging progression-free survival (PFS) and overall survival (OS). 8201 is more suitable for use after resistance to first-line or second-line treatments such as tucatinib. DESTINY-Breast03The study showed that 8201 showed better efficacy than T-DM1 in advanced HER2 positive breast cancer, and its objective response rate (ORR) and PFS were significantly better than traditional treatment options.

From the perspective of indications and treatment stages, tucatinib is mainly used for patients with advanced breast cancer who have received at least one anti-HER2 treatment regimen, especially patients with brain metastases. 8201 is regarded as a powerful late-line treatment option, which can be used to continue to control the disease after the failure of tucatinib, pertuzumab, trastuzumab and other treatments. In addition, 8201 is also being studied for HER2 low expression cancers, such as HER2-low breast cancer and even some HER2 positive gastric cancer or lung cancer patients, expanding the treatment boundaries.

Reference materials:https://www.drugs.com/